International Journal of Neuropsychopharmacology
September 1, 2026
Z. Li, D. Mukherjee, E. Dempster et al.
Abstract Background Adolescent cannabis use is associated with an increased risk of psychosis, yet the underlying molecular mechanisms remain poorly understood. Emerging evidence also pointed to genetic liability shaping individual risk of cannabis-induced psychosis. The neuregulin–ErbB4 signalling pathway, implicated in schizophrenia-related neurodevelopment, may modulate individual...
Nature Mental Health
May 1, 2026
Daniel Bello, Sophia H. Blyth, Rachel A Rabin et al.
Cannabis and tobacco use are highly prevalent among people with psychosis and are associated with medical comorbidities and poor prognosis. Concurrent use of cannabis and tobacco (‘co-use’) is rising in the general population, but has not been studied in psychosis. Given the devastating consequences of cannabis and tobacco use, it is critical to understand how their co-use affects psychiatric...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
April 1, 2026
Daniel Bello, J. Connolly, Jean Addington et al.
BACKGROUND Cannabis use is highly prevalent among people with psychotic disorders. While there is some indication that cannabis use exacerbates psychosis symptoms, its neurocognitive effects remain unclear. Co-use of cannabis and tobacco is increasing in the general population, but little is known about its effects in people with psychosis or those at risk for developing a psychotic disorder,...
Schizophrenia Research
July 30, 2024
L. Kennedy, B. Ku, J. Addington et al.
Background: Neurocognitive deficits have been widely reported in clinical high-risk for psychosis (CHR) populations. Additionally, rates of cannabis use are high among CHR youth and are associated with greater symptom severity. Cannabis use has been sometimes shown to be associated with better neurocognition in more progressed psychosis cohorts, therefore in this study we aimed to determine...
Schizophrenia Research
August 25, 2022
Olga Santesteban-Echarri, Lu Liu, Madeline Miller et al.
Cannabis use is more prevalent among youth at clinical high-risk (CHR) for psychosis than healthy controls (HC). There is mixed evidence as to whether cannabis use is associated with increased severity of attenuated psychotic symptoms (APS) or whether current cannabis use is associated with the transition to psychosis. This study aims to assess cannabis use differences between CHR youth and HC...
Yunong Bai, Simon Vandekar, Brandee Feola et al.
Abstract Objective Tobacco and cannabis are the most used substances among individuals at clinical high risk for psychosis (CHR-P), but it remains controversial whether substance use drives symptom exacerbation and psychosis transition, or vice versa. We investigated longitudinal dose-response relationships of tobacco and cannabis use with clinical presentation in a CHR-P population. Methods...